In a small retrospective study on 126 hypertensive COVID-19 patients in the province of Wuhan, Guang and colleagues found significantly lower C Reactive Protein (CRP) and procalcitonin levels in patients on ACE-inhibitors or ARBs therapy, as well as a non-significant trend toward reduced incidence of severe disease (9.3% vs. 22.9%; p = 0.061) and death (4.7% vs. 13.3% p = 0.283) [141]. The gene discussed is ACE; the disease is COVID-19.